Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized amoxicillin-clavulanic acid in hospitalized patients with COPD exacerbation
NL-OMON36305Phase 2Withdrawn
- Sponsor
- Medisch Spectrum Twente
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amoxicillin + clavulanate in chronic obstructive pulmonary disease (COPD), sponsored by Medisch Spectrum Twente. Primary endpoint: Patients achieving sputum amoxicillin level at or above MIC90 by day 3. Planned start Oct 2011; status: withdrawn.
02
Drugs
amoxicillin + clavulanate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON36305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36305.